What happened with the FDA and compounded GLP-1s, and who is still operating legally?

The situation with the FDA and compounded GLP-1s has been quite dynamic, focusing heavily on patient safety and the legal boundaries of drug compounding.

Here's a breakdown:

What Happened with the FDA and Compounded GLP-1s?

1. High Demand & Shortages: The GLP-1 receptor agonists (like semaglutide and tirzepatide, found in brand names like Ozempic, Wegovy, Mounjaro, and Zepbound) became incredibly popular for weight loss and diabetes management. This led to significant shortages of the brand-name, FDA-approved drugs.

2. Compounding Pharmacies Stepped In: During drug shortages, licensed compounding pharmacies are sometimes allowed to create versions of drugs to meet patient needs. This is where many "compounded semaglutide" or "compounded tirzepatide" products started appearing.

3. FDA's Core Concern: The Active Pharmaceutical Ingredient (API):

   • The FDA issued strong warnings because many compounding pharmacies were using salt forms of semaglutide (e.g., semaglutide sodium, semaglutide acetate) rather than the semaglutide base, which is the active ingredient in the FDA-approved drugs (Ozempic and Wegovy).
   • The FDA stated that these salt forms are not the same active ingredient as the approved drugs. Using them in compounded medications means the compounded product is an unapproved new drug, which is illegal.
   • The agency emphasized that the safety and effectiveness of these salt forms have not been established, and there are concerns about their purity, potency, and sterile compounding practices.

4. Adulterated and Misbranded Drugs: The FDA began sending warning letters to pharmacies and telehealth providers distributing compounded GLP-1s made with these unapproved salt forms, citing them as "adulterated" (because they differ in strength, quality, or purity from official standards) and "misbranded" (because their labeling might be misleading).

5. Patient Safety Focus: The FDA's primary concern throughout has been patient safety, as compounded drugs don't undergo the same rigorous testing and approval process as brand-name drugs. There have been reports of adverse events associated with improperly compounded versions.

Who Is Still Operating Legally?

Operating legally in the GLP-1 space means adhering strictly to FDA regulations and state pharmacy laws.

1. FDA-Approved Brand Name Drugs:

   • Who: Your primary care physician or a specialist (endocrinologist, obesity medicine doctor) prescribing Ozempic, Wegovy, Mounjaro, or Zepbound.
   • Why Legal: These are the fully FDA-approved medications, manufactured under strict quality controls, and dispensed by licensed pharmacies (e.g., CVS, Walgreens, local independent pharmacies).
   • How to Access: You need a valid prescription from a licensed healthcare provider based on a medical necessity, and your pharmacy will dispense the pre-filled pens from the manufacturer.

2. Legitimate Compounding (Under Specific, Limited Conditions):

   • Compounding is only legal if:
     • The FDA-approved drug is currently on the FDA's drug shortage list. (This changes, so pharmacies must monitor the list.)
     • The compounding pharmacy uses the exact same active pharmaceutical ingredient (API) as the FDA-approved drug (i.e., semaglutide base for semaglutide products, or tirzepatide base for tirzepatide products), not a salt form.
     • The compounding is done by a state-licensed compounding pharmacy (a "503A" pharmacy) or an FDA-registered outsourcing facility (a "503B" facility) for an individual patient with a valid prescription, following strict quality and safety standards.
     • It is not for commercial sale or mass production, but rather tailored for individual patient needs (e.g., different dosage form or strength if a patient has an allergy to an ingredient in the commercial product).
   • Why Legal: Compounding is a valuable service when done correctly and within legal boundaries to address specific patient needs during shortages or for unique patient formulations.
   • How to Access/Identify:
     • Seek care from licensed telehealth platforms or clinics that clearly state they partner with state-licensed 503A or 503B compounding pharmacies.
     • Ensure the pharmacy explicitly confirms they are using the semaglutide base or tirzepatide base (not salt forms) and that the brand-name drug is indeed on the FDA shortage list.
     • Ask for the pharmacy's license information and verify it with your state's Board of Pharmacy.
     • Specific Services to Look For (with the above caveats):
       • WeightWatchers Clinical (formerly Sequence): They facilitate prescriptions and partner with licensed pharmacies, often providing options for both brand-name and, when legally appropriate and compliant with FDA guidelines, compounded medications.
       • Found Health (formerly WeightWatchers Clinic, also works with Sequence): Similar to above, focusing on comprehensive weight management including medication.
       • Alpha Medical: Another telehealth platform that can prescribe GLP-1s and works with partner pharmacies.
       • Push Health, Calibrate, Noom Med: These are also platforms that connect you with prescribers who can determine if GLP-1s (brand-name or legally compounded, if applicable) are right for you.

Crucial Advice for Consumers:

• Always consult with a licensed healthcare provider. They can assess your medical history, determine if a GLP-1 is appropriate for you, and help you navigate the options.
• Be wary of "too good to be true" offers. If a service doesn't require a thorough medical consultation or offers unusually low prices without clear pharmacy information, proceed with extreme caution.
• Verify the pharmacy. Any legitimate provider should be able to tell you which pharmacy they are using, and you can check that pharmacy's license with your state's Board of Pharmacy.
• Ask about the API. Explicitly ask if the compounded product uses semaglutide base (or tirzepatide base) and if the brand-name drug is currently on the FDA shortage list. If they can't or won't answer clearly, avoid them.

The landscape is constantly evolving, but the core principle from the FDA remains: patient safety and the use of approved, verified ingredients are paramount.